BackLiminatus Pharma Class A Common Stock Overview

Liminatus Pharma Class A Common Stock Current Cash

Liminatus Pharma Class A Common Stock's current cash is $3M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$3.02M
↑ 125.46% YoYΔ $1.68M vs prior year quarter

Peer trimmed avg / median

Loading

Liminatus Pharma Class A Common Stock Current Cash History

Loading

Liminatus Pharma Class A Common Stock vs. peers: Current Cash Comparison

Loading

Liminatus Pharma Class A Common Stock Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Liminatus Pharma Class A Common Stock (LIMN) FAQ

The latest current cash for LIMN is $3M as of June 2026. That compares with $1.3M in the prior-year period — up 125.5% year over year. Investors often review this figure alongside Liminatus Pharma Class A Common Stock's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIMN's current cash moved from $1.3M to $3M — a 125.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Liminatus Pharma Class A Common Stock's operating scale or balance-sheet position.

A current cash figure of $3M for LIMN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LIMN's current cash ($3M), review year-over-year change from $1.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.